Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Semin Hematol. 2008 Jul;45(3 Suppl 2):S2–S6. doi: 10.1053/j.seminhematol.2008.07.003

Table 3.

Summary of new BCL2 inhibitors

Agent Phase Disease
Oblimersen sodium 2 FL, DLBCL, WM, MM, NHL
3 MM
Obatoclax mesylate 1 MCL
2 MDS, FL, HL
ABT-263 2 CLL, FL (combined with rituximab)

CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HL, Hodgkin’s lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; WM, Waldenstrom’s macroglobulinemia